Sander van Deventer
Job title: Executive Vice President
Sander van Deventer is Executive Vice President of Research and Product Development of uniQure, and an operational partner of Forbion Capital Partners. Sander van Deventer -a certified internist and gastroenterologist- received his medical degree and PhD from the University of Amsterdam, after defending a thesis on the biological activities of bacterial lipopolysaccharides in humans. Following board certification in internal medicine and gastroenterology he worked as a scientist in the Laboratory for Medical Biochemistry, Rockefeller University, New York. In 1995, he became professor and director of the laboratory for Experimental Internal Medicine at the Academic Medical Center in Amsterdam, and continued to work on therapeutic signal transduction inhibition, gene therapies, and (genetically engineered) probiotics. From 2001 until 2004, he chaired the Department of Gastroenterology and Hepatology at the Academic Medical Center in Amsterdam. In 1998 he co-founded Amsterdam Molecular Therapeutics (AMT N.V.) currently uniQure B.V., developing AAV-based gene therapy products and now listed on Nasdaq, acting subsequently as CSO, CMO and CEO. He was the first to administer an anti-TNF monoclonal antibody (later registered as Remicade®) to patients with Crohn’s disease, the first to infuse apolipoprotein A1 in humans and had a critical role in the development of multiple therapeutic interventions, targeting cytokines, cytokine receptors, T-cells and signal transduction pathways, using small molecules, antibodies, peptides, proteins and antisense DNA technologies. He supervised the development of Glybera, the first gene therapy product to be approved in Europe, and several other gene therapy products that currently are in clinical development.